{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:28:08Z","timestamp":1772119688657,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian Cancer (OC) prevention and early-stage detection represents a challenge due to the lack of effective surveillance. The identification of high-risk women is crucial as it provides access to prophylactic oophorectomy and reduces disease burden. Next-Generation Sequencing approaches enable the investigation of several genes associated with monogenic hereditary cancer predisposition, including ovarian cancer. For family members of patients affected by ovarian cancer without identification of a germline pathogenic variant, despite the increased empirical risk (3 times) of ovarian cancer incidence, prophylactic surgery is not indicated but may be suggested as the only efficient strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>We hereby present 2 cases of OC in which a germline heterozygous pathogenic variant in the ATM gene was identified: the first in the contest of Hereditary Breast and Ovarian Cancer (HBOC) family history and, in the other one, a late onset of neoplasms, to underline the importance of defining guidelines and management of moderate penetrance genes variants also for ovarian cancer prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Carriers of heterozygous pathogenic variants in the\n                      <jats:italic>ATM<\/jats:italic>\n                      gene have an increased risk of neoplasms incidence, mostly breast but also of OC with an absolute estimated risk of 2\u20133 times greater than the general population. For these patients there is not well-established evidence of benefit in risk reducing bilateral Salpingo-oophorectomy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-025-10357-x","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:39:56Z","timestamp":1740137996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the BRCA1\/2 genes in ovarian cancer: the role of germline pathogenic variants in the ATM gene"],"prefix":"10.1007","volume":"52","author":[{"given":"Daniele","family":"Guadagnolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"Khaleghi Hashemian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Maneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Piane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Grotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Grammatico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"De Marchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"10357_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/jhumpath2018060182","volume":"80","author":"J Prat","year":"2018","unstructured":"Prat J, D\u2019Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11\u201327. https:\/\/doi.org\/10.1016\/jhumpath2018060182","journal-title":"Hum Pathol"},{"key":"10357_CR2","doi-asserted-by":"publisher","unstructured":"Tavares V, Marques IS, Melo IG, Assis J, Pereira D, Medeiros R. (2024) Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements. Int J Mol Sci 25(3):1845. https:\/\/doi.org\/10.3390\/ijms25031845","DOI":"10.3390\/ijms25031845"},{"key":"10357_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341723","volume":"2015","author":"A Toss","year":"2015","unstructured":"Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L (2015) Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015:341723. https:\/\/doi.org\/10.1155\/2015\/341723","journal-title":"Biomed Res Int"},{"issue":"10","key":"10357_CR4","doi-asserted-by":"publisher","first-page":"e0205000","DOI":"10.1371\/journalpone0205000","volume":"13","author":"G Zheng","year":"2018","unstructured":"Zheng G, Yu H, Kanerva A, F\u00f6rsti A, Sundquist K, Hemminki K (2018) Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS ONE 13(10):e0205000. https:\/\/doi.org\/10.1371\/journalpone0205000","journal-title":"PLoS ONE"},{"issue":"1","key":"10357_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/jannonc202210004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S, ESMO Guidelines Committee Electronic address: clinicalguidelines@esmoorg (2023) Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 34(1):33\u201347. https:\/\/doi.org\/10.1016\/jannonc202210004","journal-title":"Ann Oncol"},{"key":"10357_CR6","unstructured":"Veenhuis S, van Os N, Weemaes C, et al Ataxia-Telangiectasia 1999 Mar 19 [Updated 2023 Oct 5] In: Adam MP, Feldman J, Mirzaa GM, et al, editors GeneReviews\u00ae [Internet] Seattle (WA): University of Washington, Seattle; 1993\u20132025 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26468\/"},{"issue":"4","key":"10357_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/gcc2870020412","volume":"2","author":"AL B\u00f8rresen","year":"1990","unstructured":"B\u00f8rresen AL, Andersen TI, Tretli S, Heiberg A, M\u00f8ller P (1990) Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Gene Chrom Can 2(4):339\u2013340. https:\/\/doi.org\/10.1002\/gcc2870020412","journal-title":"Gene Chrom Can"},{"key":"10357_CR8","doi-asserted-by":"publisher","first-page":"1068110","DOI":"10.3389\/fonc20231068110","volume":"13","author":"NA Borja","year":"2023","unstructured":"Borja NA, Silva-Smith R, Huang M, Parekh DJ, Sussman D, Tekin M (2023) Atypical ATMs: broadening the phenotypic spectrum of ATM-associated hereditary cancer. Front Oncol 13:1068110. https:\/\/doi.org\/10.3389\/fonc20231068110","journal-title":"Front Oncol"},{"issue":"8","key":"10357_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ng1837","volume":"38","author":"A Renwick","year":"2006","unstructured":"Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N, BCS Collaboration (UK) (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873\u2013875. https:\/\/doi.org\/10.1038\/ng1837","journal-title":"Nat Genet"},{"issue":"1","key":"10357_CR10","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/jgim2024101243","volume":"27","author":"T Pal","year":"2025","unstructured":"Pal T, Schon KR, Astiazaran-Symonds E, Balma\u00f1a J, Foulkes WD, James P, Klugman S, Livinski AA, Mak JS, Ngeow J, Voian N, Wick MJ, Hanson H, Stewart DR, Tischkowitz M, ACMG Professional Practice Guidelines Committee Electronic address: documents@acmgnet (2025) Management of individuals with heterozygous germline pathogenic variants in ATM: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 27(1):101243. https:\/\/doi.org\/10.1016\/jgim2024101243","journal-title":"Genet Med"},{"key":"10357_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/jbbacli201408001","volume":"2","author":"TM Abdel-Fatah","year":"2014","unstructured":"Abdel-Fatah TM, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S (2014) ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin 2:10\u201317. https:\/\/doi.org\/10.1016\/jbbacli201408001","journal-title":"BBA Clin"},{"issue":"1","key":"10357_CR12","doi-asserted-by":"publisher","first-page":"17808","DOI":"10.1038\/s41598-019-54116-y","volume":"9","author":"K Sugino","year":"2019","unstructured":"Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T (2019) Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Sci Rep 9(1):17808. https:\/\/doi.org\/10.1038\/s41598-019-54116-y","journal-title":"Sci Rep"},{"issue":"1","key":"10357_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, Clark R, Peel S, Gill P, Goodwin LM, Smith A, Pike KG, Barlaam B, Pass M, O\u2019Connor MJ, Smith G et al (2020) Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically. Mol Cancer Ther 19(1):13\u201325. https:\/\/doi.org\/10.1158\/1535-7163MCT-18-1394","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10357_CR14","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.3390\/ijerph19138113","volume":"19","author":"S Shah","year":"2022","unstructured":"Shah S, Cheung A, Kutka M, Sheriff M, Boussios S (2022) Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Envir Res Pub Health 19(13):8113. https:\/\/doi.org\/10.3390\/ijerph19138113","journal-title":"Int J Envir Res Pub Health"},{"key":"10357_CR15","unstructured":"Daly MB, Pal T, AlHili Z, Arun B, Buys SS, Cheng H, Churpek J, Domchek SM, Elkhanany A, Friedman S, et al NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 22025\u2014 November 7th, 2024 Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf"},{"key":"10357_CR16","doi-asserted-by":"publisher","first-page":"1030786","DOI":"10.3389\/fonc20221030786","volume":"12","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou A, Zografos E, Apostolidou K, Kyriazoglou A, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Liontos M, Dimopoulos MA, Zagouri F (2022) Germline and somatic variants in ovarian carcinoma: a next-generation sequencing (NGS) analysis. Front Oncol 12:1030786. https:\/\/doi.org\/10.3389\/fonc20221030786","journal-title":"Front Oncol"},{"issue":"5","key":"10357_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim201530","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim201530","journal-title":"Genet Med"},{"issue":"1","key":"10357_CR18","volume":"1","author":"M Holdren","year":"2023","unstructured":"Holdren M (2023) ClinGen Hereditary Breast, Ovarian, and Pancreatic Cancer Variant Curation Expert Panel M P061: ATM and PALB2 variant curation guidelines progress update: ClinGen Hereditary Breast Ovarian, and Pancreatic Cancer Variant Curation Expert Panel. Genet Med 1(1):100080","journal-title":"Genet Med"},{"issue":"11","key":"10357_CR19","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/jajhg202408022","volume":"111","author":"ME Richardson","year":"2024","unstructured":"Richardson ME, Holdren M, Brannan T, de la Hoya M, Spurdle AB, Tavtigian SV, Young CC, Zec L, Hiraki S, Anderson MJ, Walker LC, McNulty S, Turnbull C, Tischkowitz M, Schon K, Slavin T, Foulkes WD, Cline M, Monteiro AN, Pesaran T (2024) Couch FJ Specifications of the ACMG\/AMP variant curation guidelines for the analysis of germline ATM sequence variants. Am J Hum Genet 111(11):2411\u20132426. https:\/\/doi.org\/10.1016\/jajhg202408022","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10357_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41422-019-0205-0","volume":"29","author":"J Xiao","year":"2019","unstructured":"Xiao J, Liu M, Qi Y, Chaban Y, Gao C, Pan B, Tian Y, Yu Z, Li J, Zhang P, Xu Y (2019) Structural insights into the activation of ATM kinase. Cell Res 29(8):683\u2013685. https:\/\/doi.org\/10.1038\/s41422-019-0205-0","journal-title":"Cell Res"},{"key":"10357_CR21","doi-asserted-by":"publisher","first-page":"6630300","DOI":"10.1155\/2020\/6630300","volume":"2020","author":"D Hettiarachchi","year":"2020","unstructured":"Hettiarachchi D, Panchal H, Pathirana BAPS, Rathnayaka PD, Padeniya A, Lai PS, Dissanayake VHW (2020) Six Novel ATM Gene Variants in Sri Lankan Patients with Ataxia Telangiectasia. Case Rep Genet 2020:6630300. https:\/\/doi.org\/10.1155\/2020\/6630300","journal-title":"Case Rep Genet"},{"key":"10357_CR22","unstructured":"The World Ovarian Cancer Coalition Atlas Global Trends in Incidence, Mortality and Survival In World Ovarian Cancer Coalition; The World Ovarian Cancer Coalition: Toronto, ON, Canada, 2018; pp 1\u201339 Available online: https: \/\/worldovariancancercoalitionorg\/wp-content\/uploads\/2018\/10\/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018pdf (accessed on 28 October 2023)"},{"issue":"11","key":"10357_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/jnci\/dji141","volume":"97","author":"D Thompson","year":"2005","unstructured":"Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Nat Can Inst 97(11):813\u2013822. https:\/\/doi.org\/10.1093\/jnci\/dji141","journal-title":"J Nat Can Inst"},{"issue":"5","key":"10357_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gepi21971","volume":"40","author":"M Marabelli","year":"2016","unstructured":"Marabelli M, Cheng SC, Parmigiani G (2016) Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol 40(5):425\u2013431. https:\/\/doi.org\/10.1002\/gepi21971","journal-title":"Genet Epidemiol"},{"issue":"23","key":"10357_CR25","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama20186228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, Kasi PM, McWilliams RR, Petersen GM, Couch FJ (2018) Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319(23):2401\u20132409. https:\/\/doi.org\/10.1001\/jama20186228","journal-title":"JAMA"},{"issue":"4","key":"10357_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamaoncol20165194","volume":"3","author":"R Pearlman","year":"2017","unstructured":"Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Ohio Colorectal Cancer Prevention Initiative Study Group (2017) Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3(4):464\u2013471. https:\/\/doi.org\/10.1001\/jamaoncol20165194","journal-title":"JAMA Oncol"},{"issue":"15","key":"10357_CR27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO1801854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Miller MA, D Penberthy LS, Katz SJ (2019) Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 37(15):1305\u20131315. https:\/\/doi.org\/10.1200\/JCO1801854","journal-title":"J Clin Oncol"},{"issue":"24","key":"10357_CR28","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1093\/hmg\/ddx368","volume":"26","author":"AM Goldstein","year":"2017","unstructured":"Goldstein AM, Xiao Y, Sampson J, Zhu B, Rotunno M, Bennett H, Wen Y, Jones K, Vog A, Burdette L, Luo W, Zhu B, Yeager M, Hicks B, Han J, De Vivo I, Koutros S, Andreotti G, Beane-Freeman L, Purdue M et al (2017) Rare germline variants in known melanoma susceptibility genes in familial melanoma. Hum Mol Genet 26(24):4886\u20134895. https:\/\/doi.org\/10.1093\/hmg\/ddx368","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10357_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol20155495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ (2016) Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2(4):482\u2013490. https:\/\/doi.org\/10.1001\/jamaoncol20155495","journal-title":"JAMA Oncol"},{"issue":"4","key":"10357_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, Lancaster JM, Kurian AW (2021) Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Can Prev Res 14(4):433\u2013440. https:\/\/doi.org\/10.1158\/1940-6207CAPR-20-0448","journal-title":"Can Prev Res"},{"issue":"15","key":"10357_CR31","doi-asserted-by":"publisher","first-page":"11890","DOI":"10.3390\/ijms241511890","volume":"24","author":"N Cordani","year":"2023","unstructured":"Cordani N, Bianchi T, Ammoni LC, Cortinovis DL, Cazzaniga ME, Lissoni AA, Landoni F, Canova S (2023) An overview of PARP resistance in ovarian cancer from a molecular and clinical perspective. Int J Mol Sci 24(15):11890. https:\/\/doi.org\/10.3390\/ijms241511890","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10357_CR32","doi-asserted-by":"publisher","first-page":"238146831882110","DOI":"10.1177\/2381468318821103","volume":"4","author":"L Asphaug","year":"2019","unstructured":"Asphaug L, Melberg HO (2019) The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway. MDM Policy Pract 4(1):2381468318821103. https:\/\/doi.org\/10.1177\/2381468318821103","journal-title":"MDM Policy Pract"},{"key":"10357_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/jctrv2023102650","volume":"121","author":"L Incorvaia","year":"2023","unstructured":"Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A et al (2023) Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Can Treat Rew 121:102650. https:\/\/doi.org\/10.1016\/jctrv2023102650","journal-title":"Can Treat Rew"},{"key":"10357_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/PO1800091","author":"SM Nielsen","year":"2018","unstructured":"Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balma\u00f1a J, Biancolella M, Bslok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R et al (2018) Genetic testing and clinical management practices for variants in non-BRCA1\/2 breast (and breast\/ovarian) cancer susceptibility genes: an international survey by the evidence-based network for the interpretation of germline mutant alleles (ENIGMA) clinical working group. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO1800091","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10357_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-021-00248-y","volume":"21","author":"F Lesueur","year":"2022","unstructured":"Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadal\u00f3 L, Spanish ATM working group et al (2022) First international workshop of the ATM and cancer risk group (4\u20135 December 2019). Famil Can 21(2):211\u2013227. https:\/\/doi.org\/10.1007\/s10689-021-00248-y","journal-title":"Famil Can"},{"key":"10357_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/jbreast20220600337","volume":"65","author":"R Graffeo","year":"2022","unstructured":"Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE (2022) Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast (Edinburgh, Scotland) 65:32\u201340. https:\/\/doi.org\/10.1016\/jbreast20220600337","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"3","key":"10357_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/OP.21.00382","volume":"18","author":"YL Liu","year":"2022","unstructured":"Liu YL, Breen K (2022) Risk-reducing bilateral Salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract 18(3):201\u2013209","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10357_CR38","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/jmg-2024-110127","volume":"61","author":"TK Mukhtar","year":"2024","unstructured":"Mukhtar TK, Wilcox N, Dennis J, Yang X, Naven M, Mavaddat N, Perry JRB, Gardner E, Easton DF (2024) Protein-truncating and rare missense variants in ATM and CHEK2 and associations with cancer in UK Biobank whole-exome sequence data. J Med Genet 61(11):1016\u20131022. https:\/\/doi.org\/10.1136\/jmg-2024-110127","journal-title":"J Med Genet"},{"issue":"23","key":"10357_CR39","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1200\/JCO2001992","volume":"39","author":"C Gao","year":"2021","unstructured":"Gao C, Polley EC, Hart SN, Huang H, Hu C, Gnanaolivu R, Lilyquist J, Boddicker NJ, Na J, Ambrosone CB, Auer PL, Bernstein L, Burnside ES, Eliassen AH, Gaudet MM, Haiman C, Hunter DJ, Jacobs EJ, John EM, Lindstr\u00f6m S et al (2021) Risk of breast cancer among carriers of pathogenic variants in breast cancer predisposition genes varies by polygenic risk score. J Clin Oncol 39(23):2564\u20132573. https:\/\/doi.org\/10.1200\/JCO2001992","journal-title":"J Clin Oncol"},{"issue":"23","key":"10357_CR40","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.3390\/ijms242317020","volume":"24","author":"K Horackova","year":"2023","unstructured":"Horackova K, Janatova M, Kleiblova P, Kleibl Z, Soukupova J (2023) Early-onset ovarian cancer <30 years: what do we know about its genetic predisposition? Int J Mol Sci 24(23):17020. https:\/\/doi.org\/10.3390\/ijms242317020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10357_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1136\/ijgc-2022-003893","volume":"33","author":"C Marchetti","year":"2023","unstructured":"Marchetti C, Ataseven B, Cassani C, Sassu CM, Congedo L, D\u2019Indinosante M, Cappuccio S, Rhiem K, Hahnen E, Lucci Cordisco E, Arbustini E, Harter P, Minucci A, Scambia G, Fagotti A (2023) Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients. Int J Gynecol Canc 33(2):257\u2013262. https:\/\/doi.org\/10.1136\/ijgc-2022-003893","journal-title":"Int J Gynecol Canc"},{"issue":"2","key":"10357_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5468\/ogs2020632205","volume":"63","author":"SL Carbajal-Mamani","year":"2020","unstructured":"Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno JC, Cardenas-Goicoechea J (2020) Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy? Obstet Gynecol Sci 63(2):205\u2013208. https:\/\/doi.org\/10.5468\/ogs2020632205","journal-title":"Obstet Gynecol Sci"},{"issue":"6","key":"10357_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer (Tokyo, Japan) 28(6):1167\u20131180. https:\/\/doi.org\/10.1007\/s12282-020-01148-2","journal-title":"Breast Cancer (Tokyo, Japan)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10357-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:35:51Z","timestamp":1766853351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10357-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10357"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10357-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5769485\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki The study was approved from the Ethical Committee \u201cComitato Etico Territoriale Lazio Area 1\u201d, protocol 565\/2023, 21 July 2023.\n                      Informed consent.\n                      Written Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"261"}}